Pages Menu
Categories Menu

First participant randomized in REPRIEVE

The first participant has been randomized in the REPRIEVE trial! We are so excited to have reached this major milestone and are continuing to move forward to randomize many more participants into this ground breaking trial to test whether a daily dose of a statin will reduce the risk of cardiovascular disease among HIV-infected individuals.